Both in Pharmaceuticals
PUMA BIOTECHNOLOGY vs Aclaris Therapeutics
Over the past year PBYI returned +102.8% and ACRS returned +46.1%; their daily moves had a correlation of 0.31.
PBYI +102.8% ACRS +46.1%Growth of $1, one year, split-adjusted
| Metric | PBYI | ACRS |
|---|---|---|
| Price | $10.22 | $3.74 |
| Market cap | $527.6M | $579.6M |
| Today | +0.39% | −1.58% |
| 1 month | +5.7% | −12.4% |
| 6 months | +39.0% | −21.3% |
| Year to date | +71.8% | +24.3% |
| 1 year | +100.4% | +48.4% |
| Revenue growth (YoY) | +7.8% | −8.3% |
| Gross margin | 77.9% | 86.6% |
| Net margin | 14.5% | −1320.1% |
| P/E (TTM) | 19.7× | — |
| Price / sales | 2.3× | 70.5× |
| Net cash | $93.9M | $91.6M |
| Dividend yield | — | — |
| Volatility (60d) | 39.5% | 75.8% |
| Short % of float | 11.6% | 12.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).